Diagnostic Consultative Center Aleksandrovska
Sofia, Bulgaria
4 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightType 2 Diabetes+2 more
Pfizer999 enrolled181 locationsNCT07400653
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Pfizer3,501 enrolled171 locationsNCT07311850
Recruiting
Phase 2
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Chronic Spontaneous Urticaria
Pfizer200 enrolled69 locationsNCT07219615
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Heart Failure
Pfizer620 enrolled142 locationsNCT06991257
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Pfizer252 enrolled132 locationsNCT06977581
Recruiting
Phase 2
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
SynAct Pharma Aps240 enrolled11 locationsNCT06671054
Recruiting
Phase 3
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Vitiligo
Pfizer400 enrolled74 locationsNCT06163326